ATE422496T1 - Als medikamente für die behandlung von autoimmunerkrankungen geeignete substituierte pyridoä2,3-düpyrimidinderivate - Google Patents

Als medikamente für die behandlung von autoimmunerkrankungen geeignete substituierte pyridoä2,3-düpyrimidinderivate

Info

Publication number: ATE422496T1
Authority: AT; Austria
Prior art keywords: treatment; disorders; pyridoä2; düpyrimidine; medications
Prior art date: 2005-02-21

Application number

AT06707117T

Other languages

English (en)

Inventor

Jonghe Steven De

Piet Herdewijn

Ling-Jie Gao

Original Assignee

4 Aza Ip Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-21

Filing date

2006-02-21

Publication date

2009-02-15

2006-02-21 Application filed by 4 Aza Ip Nv filed Critical 4 Aza Ip Nv

2009-02-15 Application granted granted Critical

2009-02-15 Publication of ATE422496T1 publication Critical patent/ATE422496T1/de

Links

208000023275 Autoimmune disease Diseases 0.000 title 1
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
208000035475 disorder Diseases 0.000 abstract 3
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
150000001204 N-oxides Chemical class 0.000 abstract 1
206010052779 Transplant rejections Diseases 0.000 abstract 1
108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
210000003169 central nervous system Anatomy 0.000 abstract 1
229940125721 immunosuppressive agent Drugs 0.000 abstract 1
239000003018 immunosuppressive agent Substances 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1
159000000018 pyrido[2,3-d]pyrimidines Chemical class 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Psychiatry (AREA)
Oncology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
AIDS & HIV (AREA)

AT06707117T 2005-02-21 2006-02-21 Als medikamente für die behandlung von autoimmunerkrankungen geeignete substituierte pyridoä2,3-düpyrimidinderivate ATE422496T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0503506.8A GB0503506D0 (en)	2005-02-21	2005-02-21	Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders

Publications (1)

Publication Number	Publication Date
ATE422496T1 true ATE422496T1 (de)	2009-02-15

Family

ID=34401023

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06707117T ATE422496T1 (de)	2005-02-21	2006-02-21	Als medikamente für die behandlung von autoimmunerkrankungen geeignete substituierte pyridoä2,3-düpyrimidinderivate

Country Status (22)

Country	Link
US (1)	US20080312227A1 (de)
EP (1)	EP1851217B1 (de)
JP (1)	JP2008530167A (de)
KR (1)	KR20070112174A (de)
CN (1)	CN101203514A (de)
AT (1)	ATE422496T1 (de)
AU (1)	AU2006215700A1 (de)
BR (1)	BRPI0606844A2 (de)
CA (1)	CA2598465A1 (de)
DE (1)	DE602006005136D1 (de)
DK (1)	DK1851217T3 (de)
ES (1)	ES2318723T3 (de)
GB (1)	GB0503506D0 (de)
HR (1)	HRP20090208T1 (de)
IL (1)	IL185289A0 (de)
MX (1)	MX2007010156A (de)
NO (1)	NO20074207L (de)
PL (1)	PL1851217T3 (de)
PT (1)	PT1851217E (de)
RU (1)	RU2007135053A (de)
SI (1)	SI1851217T1 (de)
WO (1)	WO2006087229A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2612788A1 (en)	2005-06-24	2006-12-28	Steven Cesar Alfons De Jonghe	Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c
US9259426B2 (en) *	2006-07-20	2016-02-16	Gilead Sciences, Inc.	4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US8338435B2 (en)	2006-07-20	2012-12-25	Gilead Sciences, Inc.	Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
US10144736B2 (en) *	2006-07-20	2018-12-04	Gilead Sciences, Inc.	Substituted pteridines useful for the treatment and prevention of viral infections
WO2008009077A2 (en) *	2006-07-20	2008-01-24	Gilead Sciences, Inc.	4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
US8637531B2 (en) *	2006-12-26	2014-01-28	Gilead Sciences, Inc.	Pyrido(3,2-d)pyridmidines useful for treating viral infections
TW200840584A (en) *	2006-12-26	2008-10-16	Gilead Sciences Inc	Pyrido(3,2-d)pyrimidines useful for treating viral infections
CN102388041B (zh)	2009-02-12	2014-12-24	默克雪兰诺有限公司	2-吗啉代-吡啶并[3,2-d]嘧啶
RU2015148359A (ru)	2013-04-12	2017-05-15	Асана Биосайенсис, Ллк	Хиназолины и азахиназолины - двойные ингибиторы путей ras/raf/mek/erk и pi3k/akt/pten/mtor
CN103694255A (zh) *	2014-01-09	2014-04-02	华中师范大学	吡啶并噁嗪酮和吡啶并嘧啶酮类化合物及其制备方法与应用
GB201416186D0 (en)	2014-09-12	2014-10-29	Redx Pharma Ltd	Compounds
CU20180011A7 (es)	2015-03-04	2018-06-05	Gilead Sciences Inc	Composiciones farmacéuticas que comprenden compuestos derivados de diaminopirido (3,2-d) como moduladores de receptor de tipo toll
US10640499B2 (en)	2016-09-02	2020-05-05	Gilead Sciences, Inc.	Toll like receptor modulator compounds
PL3507276T3 (pl)	2016-09-02	2022-02-21	Gilead Sciences, Inc.	Związki modulatory receptorów toll-podobnych
GB201809460D0 (en)	2018-06-08	2018-07-25	Crt Pioneer Fund Lp	Salt form
GB201809458D0 (en)	2018-06-08	2018-07-25	Crt Pioneer Fund Lp	Salt form
WO2020057604A1 (zh)	2018-09-19	2020-03-26	正大天晴药业集团股份有限公司	Tlr8激动剂
TWI751517B (zh)	2019-04-17	2022-01-01	美商基利科學股份有限公司	類鐸受體調節劑之固體形式
TW202210480A (zh)	2019-04-17	2022-03-16	美商基利科學股份有限公司	類鐸受體調節劑之固體形式
TWI879779B (zh)	2019-06-28	2025-04-11	美商基利科學股份有限公司	類鐸受體調節劑化合物的製備方法
CN113801114B (zh) *	2020-06-11	2022-11-18	江苏恒瑞医药股份有限公司	稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用
IL300113A (en)	2020-07-28	2023-03-01	Jazz Pharmaceuticals Ireland Ltd	Compressed cyclic RAF inhibitors and methods of using them
KR102487604B1 (ko) *	2020-11-06	2023-01-12	에스케이케미칼 주식회사	히드로플루메티아지드를 유효성분으로 포함하는 TNF-α 관련 질환 예방 또는 치료용 조성물
WO2022161461A1 (zh) *	2021-01-29	2022-08-04	江苏先声药业有限公司	Sos1抑制剂及其制备方法和应用
CN118146134A (zh) *	2024-02-07	2024-06-07	南方海洋科学与工程广东省实验室(湛江)	一种3-羟基吡咯烷衍生物及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4818819A (en) *	1986-10-20	1989-04-04	The Trustees Of Princeton University	Process for the preparation of fused pyridine compounds
US5223503A (en) *	1991-04-29	1993-06-29	Eli Lilly And Company	6-substituted pyrido[2,3-d]pyrimidines as antineoplastic agents

2005
- 2005-02-21 GB GBGB0503506.8A patent/GB0503506D0/en not_active Ceased
2006
- 2006-02-21 HR HR20090208T patent/HRP20090208T1/xx unknown
- 2006-02-21 CN CNA2006800054787A patent/CN101203514A/zh active Pending
- 2006-02-21 ES ES06707117T patent/ES2318723T3/es not_active Expired - Lifetime
- 2006-02-21 PL PL06707117T patent/PL1851217T3/pl unknown
- 2006-02-21 JP JP2007555544A patent/JP2008530167A/ja not_active Withdrawn
- 2006-02-21 EP EP06707117A patent/EP1851217B1/de not_active Expired - Lifetime
- 2006-02-21 WO PCT/EP2006/001539 patent/WO2006087229A1/en not_active Ceased
- 2006-02-21 AU AU2006215700A patent/AU2006215700A1/en not_active Abandoned
- 2006-02-21 AT AT06707117T patent/ATE422496T1/de not_active IP Right Cessation
- 2006-02-21 RU RU2007135053/04A patent/RU2007135053A/ru not_active Application Discontinuation
- 2006-02-21 KR KR1020077020966A patent/KR20070112174A/ko not_active Withdrawn
- 2006-02-21 US US11/816,086 patent/US20080312227A1/en not_active Abandoned
- 2006-02-21 BR BRPI0606844-8A patent/BRPI0606844A2/pt not_active Application Discontinuation
- 2006-02-21 PT PT06707117T patent/PT1851217E/pt unknown
- 2006-02-21 CA CA002598465A patent/CA2598465A1/en not_active Abandoned
- 2006-02-21 DE DE602006005136T patent/DE602006005136D1/de not_active Expired - Fee Related
- 2006-02-21 DK DK06707117T patent/DK1851217T3/da active
- 2006-02-21 SI SI200630255T patent/SI1851217T1/sl unknown
- 2006-02-21 MX MX2007010156A patent/MX2007010156A/es not_active Application Discontinuation
2007
- 2007-08-15 IL IL185289A patent/IL185289A0/en unknown
- 2007-08-16 NO NO20074207A patent/NO20074207L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2006087229A1 (en)	2006-08-24
MX2007010156A (es)	2008-02-19
AU2006215700A1 (en)	2006-08-24
HRP20090208T1 (hr)	2009-05-31
IL185289A0 (en)	2008-02-09
DE602006005136D1 (de)	2009-03-26
PL1851217T3 (pl)	2009-07-31
DK1851217T3 (da)	2009-03-23
GB0503506D0 (en)	2005-03-30
PT1851217E (pt)	2009-05-14
SI1851217T1 (sl)	2009-06-30
ES2318723T3 (es)	2009-05-01
CN101203514A (zh)	2008-06-18
EP1851217A1 (de)	2007-11-07
JP2008530167A (ja)	2008-08-07
EP1851217B1 (de)	2009-02-11
NO20074207L (no)	2007-10-26
CA2598465A1 (en)	2006-08-24
RU2007135053A (ru)	2009-03-27
US20080312227A1 (en)	2008-12-18
KR20070112174A (ko)	2007-11-22
BRPI0606844A2 (pt)	2009-07-21

Legal Events

Date

Code

Title

Description

2009-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1851217

Country of ref document: EP

2011-11-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE422496T1 (de)	2009-02-15	Als medikamente für die behandlung von autoimmunerkrankungen geeignete substituierte pyridoä2,3-düpyrimidinderivate
PL1673092T3 (pl)	2008-01-31	Pochodne pterydyny podstawione heterocyklem i ich zastosowanie w leczeniu
CY1107264T1 (el)	2012-11-21	Αποτελεσματα καταστολης ανοσοποιησης των παραγωγων pteridine
WO2009003669A3 (en)	2009-03-19	Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
WO2006069805A3 (en)	2007-01-25	Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
EA200801757A1 (ru)	2009-08-28	Пиперидинильные производные в качестве модуляторов активности хемокинового рецептора
MX376465B (es)	2025-03-07	Compuestos de pirazolo[1,5-4]piridina sustituidos como inhibidores de la quinasa ret.
NO20075560L (no)	2007-12-20	Purin og imidazopyridin derivater for immunsuppresjon
GT200800265A (es)	2010-07-22	Pirido (3,2-e)piracinas, su uso como inhibidores de fosfadiesterasa 10, y procesos para prepararlas.
TW200640903A (en)	2006-12-01	Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity
TW200640901A (en)	2006-12-01	Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
BRPI0418112A (pt)	2007-04-17	inibidores de p-38 quinase bicìclico heterocìclicos
UA103634C2 (en)	2013-11-11	Azaindazole compounds as ccr1 receptor antagonists
TW200640906A (en)	2006-12-01	Heteroaryl substituted pyrazinyl-piperazine-piperidines with CXCR3 antagonist activity
TW200640902A (en)	2006-12-01	Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
WO2007100610A3 (en)	2008-10-30	Pyridine, pyrimidine and pyrazine derivatives as cxcr3 receptor modulators
EA201890827A1 (ru)	2018-10-31	Конденсированные производные пиразола в качестве ингибиторов киназы
MXPA04004019A (es)	2004-07-08	Derivados de pirimido?4,5-b?indol.
SG195085A1 (en)	2013-12-30	Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
WO2012040048A3 (en)	2012-05-10	Triazolopyrazinones as p2x7 receptor antagonists
MX2022006807A (es)	2022-09-12	Análogos de rapamicina y usos de estos.
NZ736055A (en)	2023-05-26	Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
WO2007064553A3 (en)	2008-07-10	Thiazole derivatives as cxcr3 receptor modulators
WO2007070433A3 (en)	2008-02-21	2-arylthiazole derivatives as cxcr3 receptor modulators
EA202190323A1 (ru)	2021-05-28	ИМИДАЗО[1,2-b]ПИРИДАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk